摘要
目的:观察德谷门冬双胰岛素与甘精胰岛素治疗2型糖尿病临床效果。方法:研究纳入我院收治的70例2型糖尿病患者(2021年6月至2022年6月)以随机数字表法进行分组,根据治疗方法不同分为观察1组与观察2组,各组35例,观察1组患者采取德谷门冬双胰岛素治疗,观察2组采取甘精胰岛素治疗,各组数据观察:治疗前与治疗后患者空腹血糖(FPG)及餐后2h血糖水平(2hPG)、糖化血红蛋白(HbA1c)等血糖相关指标变化、患者治疗后血糖达标时间与低血糖发生率、治疗依从性率以及治疗满意率情况。结果:治疗前各组患者血糖相关指标(FPG、2hPG、HbA1c)比较,P>0.05,治疗后各组患者血糖相关指标(FPG、2hPG、HbA1c)均下降,观察1组患者治疗后血糖相关指标(FPG、2hPG、HbA1c)低于观察2组患者,P<0.05;观察1组患者血糖达标时间短于观察2组患者,低血糖发生率低于观察2组,P<0.05;观察1组患者治疗依从性率以及治疗满意率均显著高于观察2组患者,P<0.05。结论:德谷门冬双胰岛素治疗2型糖尿病效果优于甘精胰岛素,患者血糖水平稳定,血糖达标时间短,患者低血糖发生率低,治疗依从性率以及治疗满意率均较高,值得应用。
Objective:To investigate the clinical efficacy of insulin degludec/insulin aspart vs insulin glargine in the treatment of type 2 diabetes mellitus(T2 DM).Methods:Included in this stuy were 70 T2 DM patients treated in our hospital between June 2021 and June 2022.The patients were divided into the study groups 1 and 2 by random number table(n=35 each).The study group 1 was treated with insulin degludec/insulin aspart,while and study group 2 was treated with insulin glargine.The two groups were observed for changes in blood glucose-related indicators such as levels of fasting blood glucose(FPG)and 2 h-postprandial blood glucose(2hPG),glycated haemoglobin A 1c(HbA1c)before and after treatment,the time to reach goals in blood glucose,incidence of hypoglycemia,treatment compliance,and patient satisfaction for the treatment.Results:Before treatment,there were no significant differences in blood glucose related indicators(FPG,2hPG,and HbA1c)between the two groups(P>0.05).After treatment,the levels of FPG,2hPG,HbA1c decrease in each group,and the levels of these blood glucose related indicators were even lower in the stuy group 1 than those in the study group 2(P<0.05).The reach goals in blood glucose was shorter in the study group 1 than that in the study group 2;the study group 1 had lower incidence of hypoglycemia compared with the study 2(P<0.05).The rates of treatment compliance and patient satisfaction for treatment were significantly higher in the study group 1 than those in the study group 2(P<0.05).Conclusion:In patients with T2 DM,insulin degludec/insulin aspart degludec aspart leads to better efficacy than insulin glargine in terms of stable blood glucose level,shorter time to reach goals in blood glucose,lower incidence of hypoglycemia,higher rates of treatment compliance and patient satisfaction for the treatment,and thus warrants wider use in clinical practice.
作者
王丽随
林慧贞
李素梅
陈友伟
WANG Lisui;LIN Huizhen;LI Sumei;CHEN Youwei(Department of Pharmacy,Putian First Hospital,Putian,Fujian 351100,China;Department of Laboratory Medicine,Putian First Hospital,Putian,Fujian 351100,China;Department of Endocrinology,Putian First Hospital,Putian,Fujian 351100,China)
出处
《广州医科大学学报》
2023年第3期54-58,共5页
Academic Journal of Guangzhou Medical University
基金
莆田学院校内科研项目(2021055)。
关键词
2型糖尿病
甘精胰岛素
德谷门冬双胰岛素
血糖相关指标
血糖达标时间
低血糖
type 2 diabetes mellitus
insulin glargine
insulin degludec/insulin aspart
blood glucose‐related indicators
time to reach goals in blood glucose
hypoglycemia
